Japanese patent granted for IntelliGel platform

The granting of a Japanese patent for the IntelliGel® platform opens a significant global market within ophthalmic medicines to Redwood Pharma. It is estimated that the total Japanese market in 2014 for prescription ophthalmic medicines was valued at USD 3.2 billion[1]. Redwood Pharma has now strengthened its commercial possiblities to exploit this market.

Redwood Pharma has worldwide rights to the IntelliGel platform within all ophthalmic uses. The platform can help reduce the number of daily instillations of our dry eye product. IntelliGel is a drug delivery platform that can control the release of medicines to prolong their effect. The platform allows for further commercial possibilities as other eye medicines can be reformulated to improve convenience, effect and perhaps even safety for patients.

IntelliGel is a cornerstone of Redwood Pharma’s technologies and we are very grateful to Broda Technologies, the licensor of IntelliGel, for successfully prosecuting this Japanese patent. The granting of the patent allows Redwood Pharma and its commercial partners to further develop and realize the potential for RP101, the Company’s lead candidate drug for treatment of Dry Eye Disease in post-menopausal women. Furthermore, it expands the use of IntelliGel in other products on the Japanese market. We look forward to further approvals that strengthen our use of technology”, says CEO Martin Vidaeus.
For more information:
Martin Vidaeus, CEO Redwood Pharma AB (publ.)
Tel: +46 (0) 70 232 29 29
E-mail: martin.vidaeus@redwoodpharma.se
About Redwood Pharma
Redwood Pharma develops ophthalmic products for unmet medical needs. The Company’s first project is the development of drug candidate RP101 with a known active substance against chronic dry eye in postmenopausal women who have moderate to severe symptoms. With the drug delivery platform IntelliGel® the release of active substances is controlled. Through the use of IntelliGel, Redwood Pharma can also improve dosing of other established drugs. Redwood Pharma’s strength lies in formulation and early clinical development. Revenues will be generated through licensing agreements with pharmaceutical companies that have capabilities to manufacture and sell commercial products worldwide.

Redwood Pharma AB (publ.) is listed on AktieTorget, a Swedish Multilateral Trading Facility (Ticker: REDW.ST, ISIN: SE008294789).
For more information see: www.redwoodpharma.com

[1] Santen Pharmaceutical 2015 Annual Report